Naphthyridine derivatives as potassium channel modulators

Details for Australian Patent Application No. 2008282118 (hide)

Owner VALEANT PHARMACEUTICALS INTERNATIONAL, INC.

Inventors Vernier, Jean-michel

Agent Griffith Hack

Pub. Number AU-A-2008282118

PCT Pub. Number WO2009/018466

Priority 12/181,126 28.07.08 US; 60/962,862 01.08.07 US

Filing date 31 July 2008

Wipo publication date 5 February 2009

International Classifications

C07D 471/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

A61K 31/4375 (2006.01)

A61P 25/08 (2006.01) Drugs for disorders of the nervous system

Event Publications

18 February 2010 PCT application entered the National Phase

  PCT publication WO2009/018466 Priority application(s): WO2009/018466

20 May 2010 Amendment Made

  The nature of the amendment is: Add co-inventor De La Rosa, Martha and amend co-inventor from Vernier, Jean-michel to Vernier, Jean-Michel

20 May 2010 Alteration of Name

  The name of the applicant has been altered to VALEANT PHARMACEUTICALS INTERNATIONAL Amendments

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008282130-Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function

2008282111-Wavefront refractions and high order aberration correction when wavefront maps involve geometrical transformations